Difference between revisions of "Racotumomab (Vaxira)"
Jump to navigation
Jump to search
m |
m |
||
| Line 5: | Line 5: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Vaxira | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Latest revision as of 23:51, 31 July 2023
This drug is currently approved in Argentina and Cuba.
Mechanism of action
From Wikipedia: Racotumomab is an anti-idiotypic mouse monoclonal antibody that mimics NGc gangliosides, thus triggering an immune response against the tumor antigen NGcGM3. Therefore, rather than being a passive antibody therapy, Racotumomab acts as a therapeutic vaccine.
Diseases for which it is used
Also known as
- Brand name: Vaxira